Keyword: Celgene

Investors are clamoring for a CVR created in the BMS-Celgene deal, but it will only pay off if the FDA approves three hot pipeline projects.

The 3-2 vote on the deal was split along the party lines, spelling trouble for future biopharma M&A deals should Democrats move into the White House.

With one member of its "big 5" already approved, Celgene has just received a second with the FDA nod for blockbuster hopeful anemia med Reblozyl.

Jeopardy game show host Alex Trebek stars in new PSA awareness campaign about pancreatic cancer risks and symptoms.

Bristol-Myers' Eliquis is keeping up with its world-beater rep, but analysts worry about I-O med Opdivo—and execs say the med faces a tough 2020.

While investors don't fancy megamergers, smaller deals in oncology could be the winning ticket, analysts have found.

Darzalex has become the first biologic approved for newly diagnosed multiple myeloma patients who are eligible for stem cell transplant.

When it comes to Roche and Spark’s $4.8 billion merger, delays are the norm. But even when there isn’t one, M&A watchers are keeping a close eye.

Novo won approval for oral semaglutide, but meanwhile, several other drugmakers are gearing up to launch anticipated drug candidates.

Low interest rates and strong stock valuations are two top reasons why U.S. drugmakers are on the move for deals.